1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 88,50 | 89,00 | 09:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.10. | Barclays initiates coverage on Abivax stock with Overweight rating | 61 | Investing.com | ||
| 10.10. | Guggenheim raises Abivax stock price target to $150 on obefazimod potential | 31 | Investing.com | ||
| 07.10. | Leerink Partners raises Abivax stock price target to $115 on IBD drug potential | 13 | Investing.com | ||
| 06.10. | Why Is Abivax Stock Trading Higher On Monday? | 11 | Benzinga.com | ||
| ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
| 06.10. | Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease | 13 | Investor's Business Daily | ||
| 06.10. | Abivax stock jumps after positive ulcerative colitis trial results | 6 | Investing.com | ||
| 06.10. | Abivax-Aktie legt nach positiven Studiendaten zu Colitis ulcerosa kräftig zu | 21 | Investing.com Deutsch | ||
| 06.10. | Abivax: Citizens bestätigt hohes Kursziel nach positiven Sicherheitsdaten | 39 | Investing.com Deutsch | ||
| 06.10. | Citizens reiterates Abivax stock rating with $114 price target | 3 | Investing.com | ||
| 06.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | 539 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| 06.10. | Abivax Reports Positive 8-Week Results From Phase 3 Trials Of Obefazimod In Ulcerative Colitis | 21 | RTTNews | ||
| 05.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data | 630 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
05.10.2025... ► Artikel lesen | |
| 01.10. | Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock | 17 | Insider Monkey | ||
| 29.09. | EQS-News: ABIVAX: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | 418 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United... ► Artikel lesen | |
| 25.09. | Abivax stock price target raised to $114 from $95 at JMP Securities | 12 | Investing.com | ||
| 25.09. | JMP Securities hebt Kursziel für Abivax auf 114 US-Dollar an | 8 | Investing.com Deutsch | ||
| 23.09. | Abivax präsentiert Phase-3-Daten für Obefazimod auf UEG-Kongress | 19 | Investing.com Deutsch | ||
| 23.09. | Abivax to present obefazimod phase 3 data at UEG meeting in October | 1 | Investing.com | ||
| 23.09. | EQS-News: ABIVAX: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting | 473 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European... ► Artikel lesen | |
| 23.09. | Abivax stock rating reiterated at Market Outperform by JMP | 6 | Investing.com |
1 2 3 4 5 Weiter >>
99 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | 0,00 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | 0,00 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| VENTYX BIOSCIENCES | 8,560 | 0,00 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | 0,00 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data | ||
| PRIME MEDICINE | 4,950 | +13,79 % | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy | ||
| ARCUS BIOSCIENCES | 19,645 | -2,41 % | Arcus Biosciences stock falls after pricing $250 million public offering | ||
| MINERALYS THERAPEUTICS | 40,830 | -0,73 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
ABIVAX SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 83,50 Euro und damit -6,18 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIVAX SA ADR finden Sie auf Wallstreet Online.